In HER2 overexpressing breast cancers, HER3 results in more oncogenic activity with HER2 than with other HER receptors [1, 5]; HER2 and HER3 are commonly overexpressed together in breast cancers [4]. This evidence concerns the gene ERBB3 and breast cancer.